论文部分内容阅读
目的观察心宝丸联合曲美他嗪对慢性心衰合并窦性心动过缓患者的心功能、血流动力学及相关指标的影响。方法 100例冠心病慢性心力衰竭患者随机分为观察组和对照组各50例。对照组在西医常规治疗的基础上采用曲美他嗪,观察组在对照组治疗的基础上采用心宝丸联合曲美他嗪。治疗12周后比较两组患者心功能、血浆NT-pro BNP、血清H-FABP水平和心电监测24h DCG。结果两组治疗后LVEF、LVEDD、LVESD、CO、SV及6min步行距离均较治疗前有改善,观察组改善的程度优于对照组(均P<0.05);治疗后观察组血浆NT-pro BNP和血清H-FABP水平均低于对照组(均P<0.05);观察组心电监测24 h DCG改善的程度优于对照组(均P<0.05);观察组临床疗效优于对照组,差异有显著性意义(P<0.05)。结论心宝丸联合曲美他嗪可明显改善慢性心衰合并窦性心动过缓患者的心脏舒缩功能,降低血浆NT-pro BNP和H-FABP水平,提高心室率。
Objective To observe the effect of Xinbao Pill combined with trimetazidine on cardiac function, hemodynamics and related indexes in patients with chronic heart failure complicated with sinus bradycardia. Methods 100 cases of CHD patients with chronic heart failure were randomly divided into observation group and control group of 50 cases. The control group was treated with trimetazidine based on routine treatment of Western medicine. The observation group was treated with triptorextrin with triptoreline on the basis of the control group. After 12 weeks of treatment, the cardiac function, plasma NT-pro BNP, serum H-FABP level and 24h DCG were compared between the two groups. Results After treatment, the LVEF, LVEDD, LVESD, CO, SV, and 6-minute walking distance in both groups improved compared with that before treatment, and the improvement in the observation group was better than that in the control group (all P <0.05) And serum H-FABP levels in the observation group were significantly lower than those in the control group (all P <0.05). The extent of improvement of DCG in the observation group at 24 h was better than that of the control group (all P <0.05) There was significant (P <0.05). Conclusion Xinbao pills combined with trimetazidine can significantly improve the patients with chronic heart failure complicated with sinus bradycardia and reduce the plasma NT-pro BNP and H-FABP levels and improve ventricular rate.